Intramuscular triamcinolone in severe asthma

Sergio Salmeron, Olivier Sitbon, Philippe Herve, Gérald Simonneau, Pierre Duroux, René Caquet, S. Scott Nicholas, Joseph C. Kidney, R. W. Fuller, Peter J. Barnes, S. Capewell, D. T. McLeod, Raja G. Ogirala, Thomas K. Aldrich, David J. Prezant, M. Henry Williams

Research output: Contribution to journalLetter

Abstract

The article by Ogirala and colleagues (Feb. 28 issue)1 concerning high-dose intramuscular triamcinolone in severe, chronic, life-threatening asthma prompts the following comments. First, in our view the patients were probably undertreated on entry into the study: the maintenance dose of prednisone was 10 mg daily or less in half the patients (Patients 2, 6, 7, 9, 10, and 12), which is a low dose for patients at risk for fatal asthma.2 Moreover, the maintenance dose of inhaled corticosteroids (triamcinolone acetonide) is not mentioned. Second, the dose of prednisone used in the study (15 mg daily) is not …

Original languageEnglish (US)
Pages (from-to)429-431
Number of pages3
JournalNew England Journal of Medicine
Volume325
Issue number6
DOIs
Publication statusPublished - Aug 8 1991

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Salmeron, S., Sitbon, O., Herve, P., Simonneau, G., Duroux, P., Caquet, R., ... Williams, M. H. (1991). Intramuscular triamcinolone in severe asthma. New England Journal of Medicine, 325(6), 429-431. https://doi.org/10.1056/NEJM199108083250613